GBLX (GB Sciences) 10-Year Share Buyback Ratio : -40.90% (As of Sep. 2024)

View and export this data going back to 2003. Start your Free Trial

What is GB Sciences 10-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. GB Sciences's current 10-Year Share Buyback Ratio was -40.90%.

GBLX's 10-Year Share Buyback Ratio is ranked worse than
81.14% of 647 companies
in the Biotechnology industry
Industry Median: -12.6 vs GBLX: -40.90

Competitive Comparison of GB Sciences's 10-Year Share Buyback Ratio

For the Biotechnology subindustry, GB Sciences's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GB Sciences's 10-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GB Sciences's 10-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where GB Sciences's 10-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

GB Sciences 10-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

GB Sciences (OTCPK:GBLX) 10-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

GB Sciences 10-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of GB Sciences's 10-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

GB Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GB Sciences Inc (OTCPK:GBLX) » Definitions » 10-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148

Website

https://www.gbsciences.com

GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments. The company's intellectual property covers various medical conditions, from which five drug development programs are in the preclinical stage of drug development including its formulations for Parkinson's disease (PD), chronic pain, cytokine release syndrome, depression, and cardiovascular therapeutic programs.

Executives

John C Poss	director, officer: Chief Executive Officer
Craig Ellins	director, 10 percent owner, officer: CEO	3035 EAST PATRICK LANE, SUITE 9, LAS VEGAS NV 89120
Lazarus Management Co Llc	10 percent owner	260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Israel Opportunities Fund Lllp	10 percent owner	C/O IBEX GP LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Investment Partners Lllp	10 percent owner	C/O IBEX INVESTORS LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Justin B Borus	10 percent owner	260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206